Gene Editing & Cell Therapy
CRISPR editing, CAR-T, AAV gene therapy, mRNA platforms, and CDMO manufacturing
Gene Editing
CRISPR PlatformsCRISPR/base/prime-editing platforms race; clinical proof-of-concept anchors the valuation
Cell Therapy
Autologous CAR-TAutologous CAR-T commercial in heme malignancies; manufacturing cost is the chief constraint
Allogeneic & iPSCAllogeneic/off-the-shelf chases scalability and cost — higher technical risk, larger prize
TIL & Solid TumorTIL & solid-tumor cell therapy push the frontier — durability of response still unproven
Gene Therapy
AAV Rare DiseaseAAV rare-disease gene therapies command premium pricing; safety is the critical risk
RNA TherapeuticsRNA therapeutics (ASO/siRNA) platforms mature, expanding into broader indications
mRNA Platforms
Vaccines & DeliverymRNA platforms seek post-pandemic use cases; delivery (LNP) tech sets the ceiling
Manufacturing & Tools
CDMO & EquipmentCGT manufacturing CDMOs & equipment sell the picks — clean beneficiary of pipeline scale-up
Theme lists curated by Claude and may have gaps; quotes live. Research only, not investment advice. · Updated 2026-06-28